Related Experiment Video

Updated: May 9, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?

Lesley-Ann Martin1, Mitch Dowsett

  • 1Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. lesley-ann.martin@icr.ac.uk

Cancer Cell
|July 13, 2013
PubMed

Insights

Targeting prosurvival BCL-2 protein with BH3 mimetics enhances endocrine therapy response in estrogen receptor-positive breast cancer. This approach also reduces tamoxifen-related side effects, showing clinical potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Estrogen receptor-positive (ER(+)) breast cancer frequently overexpresses the prosurvival BCL-2 protein.
  • BCL-2 plays a critical role in cancer cell survival and resistance to therapy.

Purpose of the Study:

  • To investigate the efficacy of targeting BCL-2 in ER(+) breast cancer.
  • To evaluate the combined effect of BCL-2 inhibition and endocrine therapy.
  • To assess the impact on tamoxifen-induced side effects.

Main Methods:

  • Utilized xenograft models derived from primary ER(+) breast tumors.
  • Administered BH3 mimetics to target BCL-2.
  • Combined BCL-2 inhibition with standard endocrine therapy (tamoxifen).
  • Monitored tumor response and endometrial tissue changes.

Main Results:

  • Targeting BCL-2 with BH3 mimetics significantly improved the response of ER(+) breast cancer xenografts to endocrine therapy.
  • The combination strategy reduced tamoxifen-induced endometrial hyperplasia.
  • Demonstrated a potential therapeutic strategy with clinical applicability.

Conclusions:

  • BCL-2 is a viable therapeutic target in ER(+) breast cancer.
  • BH3 mimetics combined with endocrine therapy offer a promising strategy to enhance treatment efficacy and mitigate side effects.
  • This approach warrants further clinical investigation for breast cancer patients.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...